NASDAQ:SPROSpero Therapeutics Stock Price, Forecast & News

Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SPRO stock has increased by 76.9% and is now trading at $13.71. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spero Therapeutics.

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Spero Therapeutics.

Spero Therapeutics Inc (NASDAQ:SPRO) issued its quarterly earnings data on Friday, May, 8th. The company reported ($1.22) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.35) by $0.13. The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $3.36 million. Spero Therapeutics had a negative net margin of 654.03% and a negative return on equity of 88.22%. View Spero Therapeutics' earnings history.

6 analysts have issued 1 year price targets for Spero Therapeutics' shares. Their forecasts range from $20.00 to $28.00. On average, they expect Spero Therapeutics' share price to reach $23.00 in the next year. This suggests a possible upside of 67.8% from the stock's current price. View analysts' price targets for Spero Therapeutics.

Media stories about SPRO stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Spero Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Spero Therapeutics.

Spero Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 623,200 shares, an increase of 8.0% from the June 15th total of 577,300 shares. Based on an average daily volume of 168,000 shares, the short-interest ratio is presently 3.7 days. Currently, 4.3% of the shares of the stock are short sold. View Spero Therapeutics' Current Options Chain.

Some companies that are related to Spero Therapeutics include DiaMedica Therapeutics (DMCAF), Athenex (ATNX), Arcus Biosciences (RCUS), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Legend Biotech (PLRX), Amphastar Pharmaceuticals (AMPH), Enanta Pharmaceuticals (ENTA), BioXcel Therapeutics (BTAI), Rhythm Pharmaceuticals (RYTM), Akero Therapeutics (AKRO), Nabriva Therapeutics (NBRV), Arcturus Therapeutics (ARCT), Phathom Pharmaceuticals (PHAT) and Retrophin (RTRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Crispr Therapeutics (CRSP), Viking Therapeutics (VKTX), Inovio Pharmaceuticals (INO), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), NVIDIA (NVDA), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Nokia Oyj (NOK) and Akoustis Technologies (AKTS).

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SPRO stock can currently be purchased for approximately $13.71.

Spero Therapeutics has a market capitalization of $282.36 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 57 workers across the globe.

The official website for Spero Therapeutics is sperotherapeutics.com.

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]